CLINICAL & PIPELINE·Drug Approval
Merck's Capvaxive Gains US FDA Pediatric Expansion, Broadening Pneumococcal Vaccine Market
Merck's Capvaxive receives US FDA approval for children and adolescents (2-17) at high risk for pneumococcal disease, expanding its market reach. This regulatory milestone, supported by STRIDE-13 data, offers broader serotype coverage than existing pediatric vaccines. For procurement and business development, this signifies increased demand potential and strategic market positioning for Merck in the vaccine segment.
90-Day Activity